Quantcast
Novartis’ canakinumab failed to improve survival in Phase III trial – Metro US

Novartis’ canakinumab failed to improve survival in Phase III trial

Logo is seen at new factory of Novartis in Stein
Logo is seen at new factory of Novartis in Stein

ZURICH (Reuters) – Novartis said on Tuesday its drug canakinumab (ACZ885) did not meet the primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer in a Phase III study, but other late-stage trials are ongoing.

The Phase III CANOPY-2 study was evaluating canakinumab in combination with the chemotherapy agent docetaxel in 237 adults with non-small cell lung cancer whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy, the Swiss drugmaker said in a statement.

The canakinumab development program continues with two Phase III non-small cell lung cancer clinical trials ongoing in first-line and adjuvant settings, Novartis said. Findings will be presented at an upcoming medical meeting.

Canakinumab is a human monoclonal antibody that could enhance anti-tumour immune response and reduce tumour cell proliferation, survival and invasiveness, Novartis said.

(Reporting by Silke Koltrowitz; Editing by Riham Alkousaa and Louise Heavens)

More from our Sister Sites